Pasireotide decreases leak rates after pancreatic resection, though significant drug cost may be prohibitive. We conducted a cost-effectiveness analysis to determine whether prophylactic pasireotide possesses a reasonable cost profile.A cost-effectiveness model compared pasireotide administration after pancreatic resection versus usual care, populated by probabilities of clinical outcomes from a randomized trial and hospital costs (2013 US$) from a university pancreatic disease center. Sensitivity analyses were performed to identify influential clinical components of the model.With the cost of pasireotide included, per patient costs of pancreatectomy, including those for readmission, were lower in the intervention arm (41,769 versus 42,159$; net savings of 390$, or 1
作者:Daniel E, Abbott;Jeffrey M, Sutton;Peter L, Jernigan;Alex, Chang;Patrick, Frye;Shimul A, Shah;Daniel P, Schauer;Mark H, Eckman;Syed A, Ahmad;Jeffrey J, Sussman
来源:Journal of surgical oncology 2016 年 113卷 7期